2024
Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial
Strober B, Mostaghimi A, Anadkat M, Thoma C, Tang M, Guercio J, Lebwohl M. Measuring GPPGA, Pain, Symptom, and Quality of Life Index Scores in Untreated Generalized Pustular Psoriasis: Results from the Placebo Group of the Effisayil-2 Trial. SKIN The Journal Of Cutaneous Medicine 2024, 8: s361. DOI: 10.25251/skin.8.supp.361.Peer-Reviewed Original ResearchGeneralized Pustular Psoriasis Physician Global AssessmentGeneralized pustular psoriasis flaresGeneralized pustular psoriasisPsoriasis Symptom ScalePlacebo-treated patientsVisual analog scalePlacebo groupDermatology Quality of Life IndexPain scoresPustular psoriasisPain visual analog scaleQuality of lifeMajority of patientsPhysician global assessmentDisease burdenLife-threatening skin diseaseQuality of Life Index scoreModerate painSevere painSterile pustulesAcute flaresAnalog scaleDisease activityQuality of Life IndexGPP flaresCharacterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry
Silverberg J, Cronin A, Jones E, Dave S, McLean R, Greenberg J, Strober B, Bieber T, Gooderham M, Paller A, Simpson E. Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry. JAAD International 2024, 15: 127-130. PMID: 38545488, PMCID: PMC10966280, DOI: 10.1016/j.jdin.2023.11.015.Peer-Reviewed Original ResearchMeaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
Papp K, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont J, Pham T, Kisa R, Napoli A, Banerjee S, Armstrong A. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary. JAMA Dermatology 2024, 160: 204-209. PMID: 38117487, PMCID: PMC10733845, DOI: 10.1001/jamadermatol.2023.5058.Peer-Reviewed Original ResearchSevere plaque psoriasisPatient Global ImpressionClinical trialsPsoriasis symptomsScore changeSigns DiaryPlaque psoriasisGlobal ImpressionWeek 16MAIN OUTCOMEPatient-reported end pointsPlacebo-controlled phase 3 clinical trialPhase 3 clinical trialsPatient-reported assessmentsPhase 3 programMeaningful change thresholdCategory improvementDisease burdenMeaningful score changesSelective TYK2 inhibitorsPatient changeBaseline scoresPsoriasisPatientsEnd point
2022
Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Valdecantos W, Brodovicz K, Lertratanakul A, Strober B. Palmoplantar Pustulosis has a Greater Disease Burden than Plaque Psoriasis: Real-World Evidence From the CorEvitas Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 8: 56-65. PMID: 39296672, PMCID: PMC11361487, DOI: 10.1177/24755303221146990.Peer-Reviewed Original ResearchPatient-reported outcomesPalmoplantar pustulosisPlaque psoriasisReal-world evidencePsoriasis RegistryDisease burdenPatient stratificationWorse patient-reported outcomesBody surface area involvementGreater impairmentMean overall painSurface area involvementVisual analog scaleRare skin diseaseReal-world studyQuality of lifeLittle real-world evidenceNeutrophilic pustulesOverall painClinical characteristicsPsoriasis AreaAnalog scaleArea involvementDisease characteristicsEffective therapy33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry
Ogdie A, Strober B, Lebwohl M. 33933 Relationship between skin involvement and disease burden in patients with mild to moderate plaque psoriasis: Real-world findings From CorEvitas’ Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab103. DOI: 10.1016/j.jaad.2022.06.444.Peer-Reviewed Original ResearchThe Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry
Lebwohl M, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Kotowsky N, Strober B. The Disease Burden of Generalized Pustular Psoriasis: Real-World Evidence From CorEvitas’ Psoriasis Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 71-78. PMID: 39296823, PMCID: PMC11361522, DOI: 10.1177/24755303221079814.Peer-Reviewed Original ResearchPlaque psoriasisReal-world evidenceMore treatment experiencePsoriasis RegistryPustular psoriasisTreatment experiencePatient-reported outcome measuresGeneralized pustular psoriasisCurrent treatment optionsFuture treatment decisionsQuality of lifeGPP treatmentNeutrophilic pustulesPatient sociodemographicsMedian painMedication useNorth American adultsSystemic diseaseDisease characteristicsTreatment optionsRecurrent flaresDisease burdenPatient outcomesTreatment decisionsOutcome measures
2021
25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry
Lebwohl M, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Strober B. 25031 Greater disease burden associated with palmoplantar pustulosis versus plaque psoriasis: Real-world evidence from the North American–based Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab4. DOI: 10.1016/j.jaad.2021.06.042.Peer-Reviewed Original Research26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry
Strober B, Kotowsky N, Medeiros R, Foster N, Janak J, Valdecantos W, Flack M, Golembesky A, Lebwohl M. 26588 Patient-reported outcomes from a large, North American-based cohort, highlight a greater disease burden for generalized pustular psoriasis vs plaque psoriasis: Real-world evidence from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab108. DOI: 10.1016/j.jaad.2021.06.451.Peer-Reviewed Original Research26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry
Strober B, Cronin A, Lin T, O’Brien J, Emeanuru K, Kang H, Gomez N, Khilfeh I, Lebwohl M. 26698 Characteristics and disease burden in patients with mild to moderate vs severe plaque psoriasis in real-world settings: Results from the Corrona Psoriasis Registry. Journal Of The American Academy Of Dermatology 2021, 85: ab113. DOI: 10.1016/j.jaad.2021.06.471.Peer-Reviewed Original Research